The Role of Serum Markers and Uterine Artery Doppler in Identifying At-Risk Pregnancies

Clinics in Perinatology

Volumn 38, Issue 1, 2011, Pages 1-19

  Tuuli, Methodius G ^a   Odibo, Anthony O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Doppler; Intrauterine growth restriction; Preeclampsia; Screening; Serum analytes

Indexed keywords

ADAM PROTEIN; ALPHA FETOPROTEIN; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ENDOGLIN; ESTRIOL; INHIBIN A; PADGEM PROTEIN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN ADAM12; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANEUPLOIDY; DOPPLER ECHOGRAPHY; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; OXIDATIVE STRESS; PARAMETRIC TEST; PATHOGENESIS; PATHOPHYSIOLOGY; PLACENTA DEVELOPMENT; PLACENTA INSUFFICIENCY; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; UTERINE ARTERY;

ANEUPLOIDY; BIOLOGICAL MARKERS; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY, HIGH-RISK; ULTRASONOGRAPHY, DOPPLER; UTERINE ARTERY;

EID: 79951817619     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.12.007     Document Type: Review

References (107)

1. McIntire D.D., Bloom S.L., Casey B.M., et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999, 340(16):1234-1238.
2. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003, 69(1):1-7.
3. Moore K.L., Persaud T.V. The developing human. Clinically oriented embryology 2007, WB Saunders, Philadelphia. 8th edition.
4. Pijnenborg R., Bland J.M., Robertson W.B., et al. The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. Placenta 1981, 2(4):303-316.
5. Burton G.J., Jauniaux E., Watson A.L. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol 1999, 181(3):718-724.
6. Burton G.J., Watson A.L., Hempstock J., et al. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J Clin Endocrinol Metab 2002, 87(6):2954-2959.
7. Jauniaux E., Hempstock J., Greenwold N., et al. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol 2003, 162(1):115-125.
8. Caniggia I., Winter J., Lye S.J., et al. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta 2000, 21(Suppl A):S25-S30.
9. Scifres C.M., Nelson D.M. Intrauterine growth restriction, human placental development and trophoblast cell death. J Physiol 2009, 587(Pt 14):3453-3458.
10. Burton G.J., Woods A.W., Jauniaux E., et al. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009, 30(6):473-482.
11. Roberts J.M., Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357(9249):53-56.
12. Roberts J.M., Taylor R.N., Musci T.J., et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989, 161(5):1200-1204.
13. Hsu C.D., Iriye B., Johnson T.R., et al. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993, 169(1):148-149.
14. Mills J.L., DerSimonian R., Raymond E., et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999, 282(4):356-362.
15. Taylor R.N., Crombleholme W.R., Friedman S.A., et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991, 165(4 Pt 1):895-901.
16. Redman C.W. Current topic: pre-eclampsia and the placenta. Placenta 1991, 12(4):301-308.
17. Thomas R.L., Blakemore K.J. Evaluation of elevations in maternal serum alpha-fetoprotein: a review. Obstet Gynecol Surv 1990, 45(5):269-283.
18. Costa S.L., Proctor L., Dodd J.M., et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better?. Placenta 2008, 29(12):1034-1040.
19. Cindrova-Davies T., Spasic-Boskovic O., Jauniaux E., et al. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol 2007, 170(5):1511-1520.
20. Hung T.H., Charnock-Jones D.S., Skepper J.N., et al. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol 2004, 164(3):1049-1061.
21. Tjoa M.L., Cindrova-Davies T., Spasic-Boskovic O., et al. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006, 169(2):400-404.
22. Redman C.W. Platelets and the beginnings of preeclampsia. N Engl J Med 1990, 323(7):478-480.
23. Bosio P.M., Cannon S., McKenna P.J., et al. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG 2001, 108(7):709-715.
24. Goetzinger K.R., Cahill A.G., Macones G.A., et al. Association of first-trimester low PAPP-A levels with preterm birth. Prenat Diagn 2010, 30(4):309-313.
25. Goetzinger K.R., Singla A., Gerkowicz S., et al. The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders. Am J Obstet Gynecol 2009, 201(4):412. e1-6.
26. Dugoff L., Hobbins J.C., Malone F.D., et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004, 191(4):1446-1451.
27. Spencer K., Cowans N.J., Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008, 28(1):7-10.
28. Spencer K., Cowans N.J., Avgidou K., et al. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008, 31(1):15-19.
29. Spencer K., Cowans N.J., Molina F., et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 2008, 31(2):147-152.
30. Spencer K., Cowans N.J., Avgidou K., et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006, 28(5):637-643.
31. Goetzl L., Krantz D., Simpson J.L., et al. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004, 104(1):30-36.
32. Smith G.C., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002, 87(4):1762-1767.
33. Towner D., Gandhi S., El Kady D. Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 2006, 194(6):1676-1681. [discussion: 1681-2].
34. Krause T.G., Christens P., Wohlfahrt J., et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome(1). Obstet Gynecol 2001, 97(2):277-282.
35. Baschat A.A., Harman C.R., Farid G., et al. Very low second-trimester maternal serum alpha-fetoprotein: association with high birth weight. Obstet Gynecol 2002, 99(4):531-536.
36. Dugoff L., Hobbins J.C., Malone F.D., et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005, 106(2):260-267.
37. Kowalczyk T.D., Cabaniss M.L., Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998, 91(3):396-400.
38. Morris R.K., Cnossen J.S., Langejans M., et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008, 8:33.
39. Ito N., Nomura S., Iwase A., et al. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun 2004, 314(4):1008-1013.
40. Iba K., Albrechtsen R., Gilpin B., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000, 149(5):1143-1156.
41. Laigaard J., Sorensen T., Placing S., et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005, 106(1):144-149.
42. Spencer K., Cowans N.J., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008, 28(3):212-216.
43. Cowans N.J., Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007, 27(3):264-271.
44. Poon L.C., Chelemen T., Granvillano O., et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008, 112(5):1082-1090.
45. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006, 27(1):13-17.
46. Chafetz I., Kuhnreich I., Sammar M., et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007, 197(1):35. e1-7.
47. Sekizawa A., Purwosunu Y., Yoshimura S., et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci 2009, 16(4):408-413.
48. Cowans N.J., Spencer K., Meiri H. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. Prenat Diagn 2008, 28(2):121-125.
49. Romero R., Kusanovic J.P., Than N.G., et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008, 199(2):122. e1-11.
50. Gonen R., Shahar R., Grimpel Y.I., et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008, 115(12):1465-1472.
51. Huppertz B., Sammar M., Chefetz I., et al. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008, 24(3):230-236.
52. Akolekar R., Syngelaki A., Beta J., et al. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn 2009, 29(12):1103-1108.
53. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008, 59:61-78.
54. Powers R.W., Roberts J.M., Cooper K.M., et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005, 193(1):185-191.
55. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
56. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278(15):12605-12608.
57. Taylor R.N., Grimwood J., Taylor R.S., et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003, 188(1):177-182.
58. Crispi F., Llurba E., Dominguez C., et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008, 31(3):303-309.
59. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775.
60. Teixeira P.G., Cabral A.C., Andrade S.P., et al. Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregnancy 2008, 27(1):65-73.
61. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46(5):1077-1085.
62. Moore Simas T.A., Crawford S.L., Solitro M.J., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197(3):244. e1-8.
63. Akolekar R., Zaragoza E., Poon L.C., et al. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(6):732-739.
64. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22(11):1021-1038.
65. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142.
66. Signore C., Mills J.L., Qian C., et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008, 28(9):852-858.
67. Baumann M.U., Bersinger N.A., Mohaupt M.G., et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199(3):266. e1-6.
68. Hsu-Lin S., Berman C.L., Furie B.C., et al. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984, 259(14):9121-9126.
69. Larsen E., Celi A., Gilbert G.E., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989, 59(2):305-312.
70. Halim A., Kanayama N., el Maradny E., et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol 1996, 174(1 Pt 1):272-277.
71. Banzola I., Farina A., Concu M., et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation. Prenat Diagn 2007, 27(11):1005-1010.
72. von Dadelszen P., Magee L.A., Roberts J.M. Subclassification of preeclampsia. Hypertens Pregnancy 2003, 22(2):143-148.
73. Toal M., Keating S., Machin G., et al. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol 2008, 198(3):330. e1-7.
74. Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004, 104(6):1367-1391.
75. Chesley's hypertensive disorders in pregnancy 2009, 193. Elsevier Inc., Oxford (UK). 3rd edition. M.D. Lindheimer, J.M. Roberts, F.G. Cunningham (Eds.).
76. Cnossen J.S., Morris R.K., ter Riet G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008, 178(6):701-711.
77. Conde-Agudelo A., Lindheimer M. Use of Doppler ultrasonography to predict pre-eclampsia. CMAJ 2008, 179(1):53. [author reply: 53-4].
78. Pretorius D.H., Nelson T.R., Baergen R.N., et al. Imaging of placental vasculature using three-dimensional ultrasound and color power Doppler: a preliminary study. Ultrasound Obstet Gynecol 1998, 12(1):45-49.
79. Konje J.C., Huppertz B., Bell S.C., et al. 3-dimensional colour power angiography for staging human placental development. Lancet 2003, 362(9391):1199-1201.
80. Merce L.T., Barco M.J., Bau S. Reproducibility of the study of placental vascularization by three-dimensional power Doppler. J Perinat Med 2004, 32(3):228-233.
81. Tuuli M.G., Houser M., Linda Odibo R.N., et al. Validation of placental vascular sonobiopsy for obtaining representative placental vascular indices by three-dimensional power Doppler ultrasonography. Placenta 2010, 31(3):192-196.
82. Merce L.T., Barco M.J., Bau S., et al. Assessment of placental vascularization by three-dimensional power Doppler "vascular biopsy" in normal pregnancies. Croat Med J 2005, 46(5):765-771.
83. Noguchi J., Hata K., Tanaka H., et al. Placental vascular sonobiopsy using three-dimensional power Doppler ultrasound in normal and growth restricted fetuses. Placenta 2009, 30(5):391-397.
84. Guiot C., Gaglioti P., Oberto M., et al. Is three-dimensional power Doppler ultrasound useful in the assessment of placental perfusion in normal and growth-restricted pregnancies?. Ultrasound Obstet Gynecol 2008, 31(2):171-176.
85. Dar P., Gebb J., Reimers L., et al. First-trimester 3-dimensional power Doppler of the uteroplacental circulation space: a potential screening method for preeclampsia. Am J Obstet Gynecol 2010, 203(3):238. e1-7.
86. Hafner E., Metzenbauer M., Stumpflen I., et al. First trimester placental and myometrial blood perfusion measured by 3D power Doppler in normal and unfavourable outcome pregnancies. Placenta 2010, 31(9):756-763.
87. Raine-Fenning N.J., Welsh A.W., Jones N.W., et al. Methodological considerations for the correct application of quantitative three-dimensional power Doppler angiography. Ultrasound Obstet Gynecol 2008, 32(1):115-117. [author reply: 117-8].
88. Raine-Fenning N.J., Nordin N.M., Ramnarine K.V., et al. Determining the relationship between three-dimensional power Doppler data and true blood flow characteristics: an in-vitro flow phantom experiment. Ultrasound Obstet Gynecol 2008, 32(4):540-550.
89. Raine-Fenning N.J., Nordin N.M., Ramnarine K.V., et al. Evaluation of the effect of machine settings on quantitative three-dimensional power Doppler angiography: an in-vitro flow phantom experiment. Ultrasound Obstet Gynecol 2008, 32(4):551-559.
90. Schulten-Wijman M.J., Struijk P.C., Brezinka C., et al. Evaluation of volume vascularization index and flow index: a phantom study. Ultrasound Obstet Gynecol 2008, 32(4):560-564.
91. Poon L.C., Maiz N., Valencia C., et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33(1):23-33.
92. Plasencia W., Maiz N., Poon L., et al. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(2):138-146.
93. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365(9461):785-799.
94. Akolekar R., Minekawa R., Veduta A., et al. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29(8):753-760.
95. Poon L.C., Kametas N.A., Maiz N., et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53(5):812-818.
96. Poon L.C., Nekrasova E., Anastassopoulos P., et al. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenat Diagn 2009, 29(6):553-559.
97. Aquilina J., Thompson O., Thilaganathan B., et al. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler. Ultrasound Obstet Gynecol 2001, 17(6):477-484.
98. Florio P., Reis F.M., Pezzani I., et al. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003, 21(2):165-169.
99. Stepan H., Unversucht A., Wessel N., et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007, 49(4):818-824.
100. Audibert F., Benchimol Y., Benattar C., et al. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther 2005, 20(1):48-53.
101. Ay E., Kavak Z.N., Elter K., et al. Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 2005, 45(4):283-288.
102. Spencer K., Yu C.K., Savvidou M., et al. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol 2006, 27(6):658-663.
103. Spencer K., Cowans N.J., Chefetz I., et al. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007, 27(3):258-263.
104. Espinoza J., Romero R., Nien J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007, 196(4):326. e1-13.
105. Spencer K., Cowans N.J., Nicolaides K.H. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32(5):622-626.
106. Spencer K., Yu C.K., Cowans N.J., et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005, 25(10):949-953.
107. Spencer K., Cowans N.J., Chefetz I., et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007, 29(2):128-134.